Discover 524 paid clinical trials in Calgary, . Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Calgary runs one of the busiest research programs in western Canada, with hundreds of studies recruiting at any given time.The Arthur J.E. Child Comprehensive Cancer Centre opened in Calgary in October 2024, making cancer research the city's fastest-growing trial area. Roughly a third of Calgary's recruiting studies are in oncology, and the rest cluster around heart failure, kidney disease, and metabolic conditions, much of it run through the University of Calgary. The city is also unusual for the volume of paediatric research at Alberta Children's Hospital, so families often find studies here that are not available elsewhere in the province.
Filter
2
Filter results
Results: 524
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Location: Calgary, Edmonton, Eugene OR, Salt Lake City UT,
Sponsor: Sumitomo Pharma America, Inc.
Sex: All
Age: 12+
Code: NCT04988555
Phase1, Phase2, Recruiting
Facilitating Physical Activity Behavior and Health Outcomes in Breast Cancer Patients Receiving Chemotherapy
for
Breast Cancer
Location: Calgary, Red Deer, Lethbridge, Medicine Hat,
Sponsor: Athabasca University
Sex: Female
Age: 18 - 70+
Code: NCT01053468
Phase2, Recruiting
Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors
for
Liver Tumors
Location: Calgary
Sponsor: Alberta Health services
Sex: All
Age: 18+
Code: NCT00691691
Phase2, Recruiting
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
for
Follicular Lymphoma (FL)
Location: Calgary, Salt Lake City UT, Los Angeles CA, Tucson AZ,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06091254
Phase3, Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
for
Metastatic Head-and-neck Squamous-cell Carcinoma,
Location: Calgary, Edmonton, Los Angeles CA, Gilbert AZ,
Sponsor: AVEO Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT06064877
Phase3, Recruiting
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma